Cargando…
Clinical Outcomes of Uterine Body Cancers Treated in a Tertiary Cancer Center
Objectives This article reports the clinical outcomes of uterine body cancers in South Indian population. The primary outcome of our study was overall survival (OS). The secondary outcomes were disease-free survival (DFS), patterns of recurrence, toxicities of radiation treatment, and the associati...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Thieme Medical and Scientific Publishers Pvt. Ltd.
2022
|
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9970755/ https://www.ncbi.nlm.nih.gov/pubmed/36860588 http://dx.doi.org/10.1055/s-0042-1757550 |
_version_ | 1784897966469808128 |
---|---|
author | Muthulingeshkumar, K. Pandjatcharam, Jagadesan Chaturvedula, Latha |
author_facet | Muthulingeshkumar, K. Pandjatcharam, Jagadesan Chaturvedula, Latha |
author_sort | Muthulingeshkumar, K. |
collection | PubMed |
description | Objectives This article reports the clinical outcomes of uterine body cancers in South Indian population. The primary outcome of our study was overall survival (OS). The secondary outcomes were disease-free survival (DFS), patterns of recurrence, toxicities of radiation treatment, and the association of patient, disease, and treatment characteristics with survival and recurrence. Materials and Methods Records of the patients diagnosed as malignancy in uterus and treated with surgery alone or with adjuvant treatment from January 2013 to December 2017 were retrieved after Institute Ethics Committee approval. Demographic, surgical, histopathology, and adjuvant treatment details were retrieved. Patients of endometrial adenocarcinoma were stratified according to the European Society of Medical Oncology/European Society of Gynaecological Oncology/European Society for Radiotherapy and Oncology consensus for analysis and overall outcomes irrespective of histology were also analyzed. Statistical Analysis For the survival analysis, Kaplan–Meier survival estimator was used. Cox regression was used to test the significance of association of factors with outcomes in terms of hazard ratio (HR). Results A total of 178 patient records were retrieved. The median follow-up of all patients was 30 months (0.5–81 months). The median age of the population was 55 years. Most common histology was endometrioid type of adenocarcinoma (89%), sarcomas comprised only 4%. The mean OS of all patients was 68 months ( n = 178), median was not reached. Five-year OS was 79 %. Five-year OS rates observed in low, intermediate, high-intermediate, and high-risk were 91, 88, 75, and 81.5%, respectively. The mean DFS was 65 months, median not reached. The 5-year DFS was 76%. The 5-year DFS rates observed were 82, 95, 80, and 81.5% for low, intermediate, high-intermediate, and high-risk, respectively. Univariate analysis using Cox regression showed increase in hazard for death in case of node positivity, HR 3.96 ( p 0.033). The HR for disease recurrence was 0.35 ( p = 0.042) in patients who had received adjuvant radiation therapy. No other factors had any significant impact on death or disease recurrence. Conclusion The survival outcomes in terms of DFS and OS were comparable with other Indian and Western data reported in the published literature. |
format | Online Article Text |
id | pubmed-9970755 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Thieme Medical and Scientific Publishers Pvt. Ltd. |
record_format | MEDLINE/PubMed |
spelling | pubmed-99707552023-02-28 Clinical Outcomes of Uterine Body Cancers Treated in a Tertiary Cancer Center Muthulingeshkumar, K. Pandjatcharam, Jagadesan Chaturvedula, Latha South Asian J Cancer Objectives This article reports the clinical outcomes of uterine body cancers in South Indian population. The primary outcome of our study was overall survival (OS). The secondary outcomes were disease-free survival (DFS), patterns of recurrence, toxicities of radiation treatment, and the association of patient, disease, and treatment characteristics with survival and recurrence. Materials and Methods Records of the patients diagnosed as malignancy in uterus and treated with surgery alone or with adjuvant treatment from January 2013 to December 2017 were retrieved after Institute Ethics Committee approval. Demographic, surgical, histopathology, and adjuvant treatment details were retrieved. Patients of endometrial adenocarcinoma were stratified according to the European Society of Medical Oncology/European Society of Gynaecological Oncology/European Society for Radiotherapy and Oncology consensus for analysis and overall outcomes irrespective of histology were also analyzed. Statistical Analysis For the survival analysis, Kaplan–Meier survival estimator was used. Cox regression was used to test the significance of association of factors with outcomes in terms of hazard ratio (HR). Results A total of 178 patient records were retrieved. The median follow-up of all patients was 30 months (0.5–81 months). The median age of the population was 55 years. Most common histology was endometrioid type of adenocarcinoma (89%), sarcomas comprised only 4%. The mean OS of all patients was 68 months ( n = 178), median was not reached. Five-year OS was 79 %. Five-year OS rates observed in low, intermediate, high-intermediate, and high-risk were 91, 88, 75, and 81.5%, respectively. The mean DFS was 65 months, median not reached. The 5-year DFS was 76%. The 5-year DFS rates observed were 82, 95, 80, and 81.5% for low, intermediate, high-intermediate, and high-risk, respectively. Univariate analysis using Cox regression showed increase in hazard for death in case of node positivity, HR 3.96 ( p 0.033). The HR for disease recurrence was 0.35 ( p = 0.042) in patients who had received adjuvant radiation therapy. No other factors had any significant impact on death or disease recurrence. Conclusion The survival outcomes in terms of DFS and OS were comparable with other Indian and Western data reported in the published literature. Thieme Medical and Scientific Publishers Pvt. Ltd. 2022-11-02 /pmc/articles/PMC9970755/ /pubmed/36860588 http://dx.doi.org/10.1055/s-0042-1757550 Text en MedIntel Services Pvt Ltd. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. ( https://creativecommons.org/licenses/by-nc-nd/4.0/ ) https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License, which permits unrestricted reproduction and distribution, for non-commercial purposes only; and use and reproduction, but not distribution, of adapted material for non-commercial purposes only, provided the original work is properly cited. |
spellingShingle | Muthulingeshkumar, K. Pandjatcharam, Jagadesan Chaturvedula, Latha Clinical Outcomes of Uterine Body Cancers Treated in a Tertiary Cancer Center |
title | Clinical Outcomes of Uterine Body Cancers Treated in a Tertiary Cancer Center |
title_full | Clinical Outcomes of Uterine Body Cancers Treated in a Tertiary Cancer Center |
title_fullStr | Clinical Outcomes of Uterine Body Cancers Treated in a Tertiary Cancer Center |
title_full_unstemmed | Clinical Outcomes of Uterine Body Cancers Treated in a Tertiary Cancer Center |
title_short | Clinical Outcomes of Uterine Body Cancers Treated in a Tertiary Cancer Center |
title_sort | clinical outcomes of uterine body cancers treated in a tertiary cancer center |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9970755/ https://www.ncbi.nlm.nih.gov/pubmed/36860588 http://dx.doi.org/10.1055/s-0042-1757550 |
work_keys_str_mv | AT muthulingeshkumark clinicaloutcomesofuterinebodycancerstreatedinatertiarycancercenter AT pandjatcharamjagadesan clinicaloutcomesofuterinebodycancerstreatedinatertiarycancercenter AT chaturvedulalatha clinicaloutcomesofuterinebodycancerstreatedinatertiarycancercenter |